1-Slide U54 summary received from the NCI

Bay Area & Anderson Team Against Acquired Resistance – U54 Program

Bay Area & Anderson Team Against Acquired Resistance – U54 Program (BAATAAR-UP)

Trever Bivona, MD, PhD (contact) & Jack Roth, MD; UCSF and MD Anderson Cancer Center

- EGFR/KRAS deregulation
- Survival pathways (YAP/NFκB)
- Fibroblast/ECM/TiME



(NSCLC)

➢ *How do oncogenic EGFR and KRAS (G12C) cells in NSCLC mechanistically achieve acquired resistance?*

- **P1 *Clinical tumor-TME acquired resistance (Translational)***
  - ✓ *Tumor macrophages and CAFs in promoting acquired resistance via paracrine signaling interactions*
  - ✓ *Clinical specimens (on treatment biopsies), patient-derived models*
  - ✓ *Genetic, proteomic, pharmacologic, spatial analyses tools*

- **P2 *PDX tumor-TME acquired resistance (Translational)***
  - ✓ *Immune-suppressive TME, macrophage and fibroblast signaling*
  - ✓ *Humanized mouse models (PDX, PDO)*
  - ✓ *Pathway targeting with known and identified TME combos*

- **P3 *PDO tumor-TME acquired Resistance (Basic)***
  - ✓ *TME effects, signaling interactions on resistance mechanisms*
  - ✓ *PDOs with intact TME*
  - ✓ *Synthetic lethal (CRISPR KO) and proteomic profiling*

- ***Data Science Core***
  - ✓ *Generate, analyze, and store all multi-parameter data; central hub*

- ***Administrative Core***
  - ✓ *Centralize BAATAAR-UP coordination; similar to DRSN Admin Core*